Straight To The Source: Treating Depression By Growing New Brain Cells
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A short decade after the discovery that adult humans generate new brain cells and only a few years after neurogenesis was linked with depression, BrainCells - the lead company in the field - already has positive clinical data for its small-molecule neurogenesis stimulating candidate for treatment of major depressive disorder
You may also be interested in...
Big Pharma Needs A Nudge To Make More Deals In Neuroscience Space
Neurology field is a “sleeper” deal category, experts say, with lots of unmet need, scientific advances and even blockbuster opportunities.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product